Apex Biotechnology Revenue vs. EBITDA
| 1733 Stock | TWD 28.50 0.15 0.53% |
For Apex Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Apex Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Apex Biotechnology Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Apex Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Apex Biotechnology Corp over time as well as its relative position and ranking within its peers.
Apex |
Apex Biotechnology Corp EBITDA vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Apex Biotechnology's current stock value. Our valuation model uses many indicators to compare Apex Biotechnology value to that of its competitors to determine the firm's financial worth. Apex Biotechnology Corp is rated fourth in revenue category among its peers. It is number one stock in ebitda category among its peers totaling about 0.14 of EBITDA per Revenue. The ratio of Revenue to EBITDA for Apex Biotechnology Corp is roughly 7.27 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Apex Biotechnology's earnings, one of the primary drivers of an investment's value.Apex Revenue vs. Competition
Apex Biotechnology Corp is rated fourth in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 26.95 Billion. Apex Biotechnology holds roughly 2.13 Billion in revenue claiming about 8% of equities under Health Care industry.
Apex EBITDA vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Apex Biotechnology |
| = | 2.13 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Apex Biotechnology |
| = | 293.14 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Apex EBITDA Comparison
Apex Biotechnology is currently under evaluation in ebitda category among its peers.
Apex Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Apex Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Apex Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Apex Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Apex Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of medical devices by using biosensor technology worldwide. Apex Biotechnology Corp. was founded in 1997 and is headquartered in Hsinchu, Taiwan. APEX BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.
Apex Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Apex Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Apex Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Apex Biotechnology's important profitability drivers and their relationship over time.
Use Apex Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Apex Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apex Biotechnology will appreciate offsetting losses from the drop in the long position's value.Apex Biotechnology Pair Trading
Apex Biotechnology Corp Pair Trading Analysis
The ability to find closely correlated positions to Apex Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Apex Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Apex Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Apex Biotechnology Corp to buy it.
The correlation of Apex Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Apex Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Apex Biotechnology Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Apex Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Apex Biotechnology position
In addition to having Apex Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Drugs Thematic Idea Now
Drugs
Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. The Drugs theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Drugs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Apex Stock Analysis
When running Apex Biotechnology's price analysis, check to measure Apex Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apex Biotechnology is operating at the current time. Most of Apex Biotechnology's value examination focuses on studying past and present price action to predict the probability of Apex Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apex Biotechnology's price. Additionally, you may evaluate how the addition of Apex Biotechnology to your portfolios can decrease your overall portfolio volatility.